Cancer Treatments
Chronic Stress and Obesity May Promote Pancreatic Cancer Growth via CREB Activation, Study Suggests
Key Takeaways Stress and obesity may contribute to pancreatic cancer: Both factors activate biological pathways that may accelerate tumor growth. Women may be more vulnerable: Hormonal differences could heighten stress-related …Metformin and Syrosingopine: Diabetes and Blood Pressure Drugs Show Promise Against Cancer in Early Study
Key Takeaways: A drug pairing of metformin (diabetes medication) and syrosingopine (blood pressure drug) shows potential for starving cancer cells. The combo blocks two critical energy pathways cancer cells …
Prostate Cancer MRI Scans May Underestimate Tumor Size: UCLA Study Warns of Treatment Risks
Key Takeaways: Prostate cancer is the second leading cause of cancer death in U.S. men, but early detection boosts survival rates to nearly 100%. Age, family history, and race …
Short-Term Rapamycin Treatment May Be Sufficient for Lifespan Extension, Reducing the Need for Lifelong Use
A team of researchers from the Max Planck Institute for Biology of Ageing has revealed that brief exposure to the macrolide drug rapamycin could have similar effects on lifespan …
Possible Solution for Cancer Pain Through Electrical Stimulation of the Pituitary Gland
Globally, the prevalence of cancer has risen, with a projected increase in the number of annual cases from 14 million to 32 million in 2032. If detected early, cancer …
Vibrating Molecules Can Kill 99% of Cancer Cells Without Hurting Healthy Tissue
Researchers have just developed a promising strategy to combat melanoma, offering a potential new pathway in cancer treatment. This article explores their innovative approach, poised to change the landscape …
Durvalumab (Imfinzi) Boosts Survival in Early-Stage Lung Cancer: What Patients Should Know
Key Takeaways: Adding Durvalumab (Imfinzi) to chemotherapy before and after surgery significantly improves outcomes for early-stage non-small cell lung cancer (NSCLC). Patients receiving Durvalumab had a 73% chance of …
Immunotherapy Transforms Melanoma Outcomes: French Study Highlights Progress, Challenges, and Key Survival Data
Key Takeaways: Dual immunotherapy (anti-PD-1 + anti-CTLA-4) achieves 77% survival at 6.5 years in metastatic melanoma, compared to 69% with anti-PD-1 alone. Combination therapy boosts efficacy but increases severe …